NCI- and investigator sponsored trials

Thirteen clinical studies are conducted with intravenous belinostat under sponsorship of the National Cancer Institute or other groups. These trials are complementary to the Topotarget A/S' clinical program, including single-agent treatment with IV belinostat in platinum resistant ovarian cancer, mesothelioma, hepatocellular carcinoma, thymic malignancies, B-cell lymphoma, AML, myelodysplastic syndrome (MDS) and lung cancer, both non-small cell and small cell. Combination studies are in progress with bortezomib, cis-retinoic acid, cisplatin, carboplatin, etoposide, and 5-azacytidine.

Three investigator sponsored trials are conducted in NSCLS, acute leukemia, or MDS.